Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

957.00 +19.39 (+2.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 547,375
Open 926.94
Bid (Size) 954.85 (1)
Ask (Size) 958.50 (1)
Prev. Close 937.61
Today's Range 926.94 - 958.13
52wk Range 684.80 - 998.33
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
Via Benzinga

Performance

YTD
+5.75%
+5.75%
1 Month
+0.64%
+0.64%
3 Month
+1.25%
+1.25%
6 Month
+17.15%
+17.15%
1 Year
+26.94%
+26.94%

More News

Read More
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
Via InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Via Benzinga
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
Via Benzinga
Regeneron Earnings Miss; Biotech Giant's Stock Falls
Via Investor's Business Daily
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Via Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
Via Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Via The Motley Fool
Regeneron Reports First Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Via Benzinga
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Small-Cap Growth Stocks With Room To Run
Via The Motley Fool
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
From Kirby McInerney LLP
Via GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.